TY - STD TI - National comprehensive cancer network clinical practice guidelines in oncology colon cancer Version 3. 2015. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed 6 Aug 2015. UR - http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf ID - ref1 ER - TY - JOUR AU - Van Cutsem, E. AU - Cervantes, A. AU - Nordlinger, B. AU - Arnold, D. PY - 2014 DA - 2014// TI - Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu260 DO - 10.1093/annonc/mdu260 ID - Van Cutsem2014 ER - TY - STD TI - Japanese society for cancer of the colon and rectum: JSCCR Guidelines 2014 for the treatment of colorectal cancer. Tokyo: Kanehara & Co., Ltd; 2010. ID - ref3 ER - TY - JOUR AU - Heinemann, V. AU - Weikersthal, L. F. AU - Decker, T. AU - Kiani, A. AU - Vehling-Kaiser, U. AU - Al-Batran, S. E. PY - 2014 DA - 2014// TI - FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial JO - Lancet Oncol. VL - 10 UR - https://doi.org/10.1016/S1470-2045(14)70330-4 DO - 10.1016/S1470-2045(14)70330-4 ID - Heinemann2014 ER - TY - JOUR AU - Venook, A. P. AU - Niedzwiecki, D. AU - Lenz, H. AU - Innocenti, F. AU - Mahoney, M. R. AU - O’Neil, B. H. PY - 2014 DA - 2014// TI - CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) JO - J Clin Oncol VL - 32 ID - Venook2014 ER - TY - JOUR AU - Mellas, N. AU - Benbrahim, Z. AU - Mesbahi, O. PY - 2014 DA - 2014// TI - Colorectal cancer: new developments after the 2013 ECCO/ESMO congress JO - Chin J Cancer. VL - 33 ID - Mellas2014 ER - TY - JOUR AU - Chibaudel, B. AU - Bonnetain, F. AU - Tournigand, C. AU - Larauze, M. H. AU - Gramont, A. AU - Laurent-Puig, P. PY - 2015 DA - 2015// TI - STRATEGIC-1: a multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer JO - BMC Cancer VL - 15 UR - https://doi.org/10.1186/s12885-015-1503-7 DO - 10.1186/s12885-015-1503-7 ID - Chibaudel2015 ER - TY - JOUR AU - Fuchs, C. S. AU - Marshall, J. AU - Mitchell, E. AU - Wierzbicki, R. AU - Ganju, V. AU - Jeffery, M. PY - 2007 DA - 2007// TI - Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2007.11.3357 DO - 10.1200/JCO.2007.11.3357 ID - Fuchs2007 ER - TY - JOUR AU - Haller, D. G. AU - Cassidy, J. AU - Clarke, S. J. AU - Cunningham, D. AU - Cutsem, E. AU - Hoff, P. M. PY - 2008 DA - 2008// TI - Potential regional differences for the tolerability profiles of fluoropyrimidines JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.15.2090 DO - 10.1200/JCO.2007.15.2090 ID - Haller2008 ER - TY - JOUR AU - Souglakos, J. AU - Ziras, N. AU - Kakolyris, S. AU - Boukovinas, I. AU - Kentepozidis, N. AU - Makrantonakis, P. PY - 2012 DA - 2012// TI - Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) JO - Br J Cancer VL - 106 UR - https://doi.org/10.1038/bjc.2011.594 DO - 10.1038/bjc.2011.594 ID - Souglakos2012 ER - TY - JOUR AU - Pectasides, D. AU - Papaxoinis, G. AU - Kalogeras, K. T. AU - Eleftheraki, A. G. AU - Xanthakis, I. AU - Makatsoris, T. PY - 2012 DA - 2012// TI - XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis JO - BMC Cancer VL - 12 UR - https://doi.org/10.1186/1471-2407-12-271 DO - 10.1186/1471-2407-12-271 ID - Pectasides2012 ER - TY - JOUR AU - Ducreux, M. AU - Adenis, A. AU - Pignon, J. P. AU - François, E. AU - Chauffert, B. AU - Ichanté, J. L. AU - Boucher, E. PY - 2013 DA - 2013// TI - Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study) JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2012.12.011 DO - 10.1016/j.ejca.2012.12.011 ID - Ducreux2013 ER - TY - JOUR AU - Schmiegel, W. AU - Reinacher-Schick, A. AU - Arnold, D. AU - Kubicka, S. AU - Freier, W. AU - Dietrich, G. PY - 2013 DA - 2013// TI - Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mdt028 DO - 10.1093/annonc/mdt028 ID - Schmiegel2013 ER - TY - JOUR AU - Hamamoto, Y. AU - Yamaguchi, T. AU - Nishina, T. AU - Yamazaki, K. AU - Ura, T. AU - Nakajima, T. PY - 2014 DA - 2014// TI - A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study) JO - Oncologist. VL - 19 UR - https://doi.org/10.1634/theoncologist.2014-0159 DO - 10.1634/theoncologist.2014-0159 ID - Hamamoto2014 ER - TY - JOUR AU - Beutler, E. AU - Gelbart, T. AU - Demina, A. PY - 1998 DA - 1998// TI - Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism JO - Proc Natl Acad Sci VL - 95 UR - https://doi.org/10.1073/pnas.95.14.8170 DO - 10.1073/pnas.95.14.8170 ID - Beutler1998 ER - TY - JOUR AU - Hoskins, J. a. n. e. l. l. e. M. AU - Goldberg, R. i. c. h. a. r. d. M. AU - Pingping, Q. u. PY - 2007 DA - 2007// TI - UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters JO - J Natl Cancer Inst VL - 99 UR - https://doi.org/10.1093/jnci/djm115 DO - 10.1093/jnci/djm115 ID - Hoskins2007 ER - TY - JOUR AU - Sai, K. AU - Saito, Y. AU - Sakamoto, H. AU - Shirao, K. AU - Kurose, K. AU - Saeki, M. PY - 2008 DA - 2008// TI - Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients JO - Cancer Lett VL - 261 UR - https://doi.org/10.1016/j.canlet.2007.11.009 DO - 10.1016/j.canlet.2007.11.009 ID - Sai2008 ER - TY - JOUR AU - Takano, M. AU - Kato, M. AU - Yoshikawa, T. AU - Sasaki, N. AU - Hirata, J. AU - Furuya, K. PY - 2009 DA - 2009// TI - Clinical significance of UDP-glucuronosyl transferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study JO - Oncology. VL - 76 UR - https://doi.org/10.1159/000209335 DO - 10.1159/000209335 ID - Takano2009 ER - TY - JOUR AU - O’Dwyer, P. J. AU - Catalano, R. B. PY - 2006 DA - 2006// TI - Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2006.07.3031 DO - 10.1200/JCO.2006.07.3031 ID - O’Dwyer2006 ER - TY - JOUR AU - Kim, K. P. AU - Hong, Y. S. AU - Lee, J. L. AU - Bae, K. S. AU - Kim, H. S. AU - Shin, J. G. PY - 2015 DA - 2015// TI - A phase I study of UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRI JO - Oncology. VL - 88 UR - https://doi.org/10.1159/000368674 DO - 10.1159/000368674 ID - Kim2015 ER - TY - STD TI - National Cancer Institute, Cancer therapy evaluation program. common terminology criteria for adverse events (CTCAE). Version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 6 Aug 2015. UR - http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf ID - ref21 ER - TY - JOUR AU - Muro, K. AU - Boku, N. AU - Shimada, Y. PY - 2010 DA - 2010// TI - Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second- line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study) JO - Lancet Oncol. VL - 11 UR - https://doi.org/10.1016/S1470-2045(10)70181-9 DO - 10.1016/S1470-2045(10)70181-9 ID - Muro2010 ER - TY - JOUR AU - Bennouna, J. AU - Sastre, J. AU - Arnold, D. AU - Österlund, P. AU - Greil, R. AU - Cutsem, E. PY - 2013 DA - 2013// TI - Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial JO - Lancet Oncol. VL - 14 UR - https://doi.org/10.1016/S1470-2045(12)70477-1 DO - 10.1016/S1470-2045(12)70477-1 ID - Bennouna2013 ER - TY - JOUR AU - Nakayama, G. AU - Uehara, K. AU - Ishigure, K. AU - Yokoyama, H. AU - Ishiyama, A. AU - Eguchi, T. PY - 2012 DA - 2012// TI - The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801) JO - Cancer Chemother Pharmacol VL - 70 UR - https://doi.org/10.1007/s00280-012-1948-1 DO - 10.1007/s00280-012-1948-1 ID - Nakayama2012 ER - TY - JOUR AU - Shin, S. J. AU - Ahn, J. B. AU - Choi, H. J. AU - Cho, B. C. AU - Jeung, H. C. AU - Rha, S. Y. PY - 2008 DA - 2008// TI - The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer JO - Cancer Chemother Pharmacol VL - 61 UR - https://doi.org/10.1007/s00280-007-0447-2 DO - 10.1007/s00280-007-0447-2 ID - Shin2008 ER - TY - JOUR AU - Hong, Y. S. AU - Lee, J. AU - Kim, K. P. AU - Lee, J. L. AU - Park, Y. S. AU - Park, J. O. PY - 2013 DA - 2013// TI - Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy JO - Invest New Drugs VL - 31 UR - https://doi.org/10.1007/s10637-012-9853-3 DO - 10.1007/s10637-012-9853-3 ID - Hong2013 ER - TY - JOUR AU - Bao, H. Y. AU - Fang, W. J. AU - Zhang, X. C. AU - Shi, G. M. AU - Huang, S. AU - Yu, L. F. PY - 2011 DA - 2011// TI - Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin JO - Cancer Chemother Pharmacol VL - 67 UR - https://doi.org/10.1007/s00280-010-1301-5 DO - 10.1007/s00280-010-1301-5 ID - Bao2011 ER - TY - JOUR AU - Cui, F. AU - Chen, J. Z. AU - Wan, C. AU - Chen, B. AU - Luo, R. C. AU - Zheng, H. PY - 2009 DA - 2009// TI - Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer JO - Zhonghua Wei Chang Wai Ke Za Zhi. VL - 12 ID - Cui2009 ER - TY - JOUR AU - Zhou, J. F. AU - Bai, C. M. AU - Cheng, Y. J. AU - Jia, N. AU - Shao, Y. J. AU - Chen, S. C. PY - 2009 DA - 2009// TI - Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin JO - Zhongguo Yi Xue Ke Xue Yuan Xue Bao. VL - 31 ID - Zhou2009 ER - TY - JOUR AU - Giantonio, B. J. AU - Catalano, P. J. AU - Meropol, N. J. AU - O’Dwyer, P. J. AU - Mitchell, E. P. AU - Alberts, S. R. AU - Schwartz, M. A. PY - 2007 DA - 2007// TI - Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.6305 DO - 10.1200/JCO.2006.09.6305 ID - Giantonio2007 ER - TY - STD TI - International conference on harmonization of technical requirements for registration of pharmaceutical for human use, ICH harmonized tripartite guideline for good clinical practice, efficacy 6, http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. Accessed 8 Aug 2016. UR - http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf ID - ref31 ER -